News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MorphoSys AG Release: AbD Serotec Receives Large Research Antibody Order From Proteomics Specialist Proteomika


3/5/2008 9:59:26 AM

MARTINSRIED, Germany, March 5, 2008 (PRIME NEWSWIRE) -- MorphoSys AG (FSE:MOR) (Prime Standard Segment:TecDAX) today announced that its AbD Serotec business unit has received a multiple research antibody order from Proteomika SL, a Spanish biotechnology company specializing in biomarker discovery. Proteomika has ordered novel, HuCAL-based, research antibodies against a broad range of target molecules in addition to the production of antigen material at AbD Serotec. AbD Serotec will apply MorphoSys's HuCAL GOLD antibody technology and the proprietary Antigen Expression System AgX(tm). The order ranks Proteomika among the largest customers for custom monoclonals services provided by AbD Serotec. Financial details of the agreement were not disclosed.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES